510(k) K191144
K191144 is an FDA 510(k) premarket notification submitted by Mauna Kea Technologies for the device "Cellvizio 100 Series System with Confocal Miniprobes". The FDA issued a decision of Substantially Equivalent on January 24, 2020. The device falls under product code OWN (Confocal Optical Imaging), a Class II device regulated under 21 CFR 876.1500. Mauna Kea Technologies has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- January 24, 2020
- Date Received
- April 30, 2019
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Confocal Optical Imaging
- Device Class
- Class II
- Regulation Number
- 876.1500
- Review Panel
- SU
- Submission Type
Collection of light signals for visualization of cellular microstructures.